The agency put TB medications into three classes according to when they should be used. WHO no longer recommends the drugs kanamycin and capreomycin, which put patients at an increased risk of treatment failure and relapse when used in longer multidrug-resistant TB regimens.
WHO also recommends providers treat all TB patients with oral drugs as opposed to injectable drugs since oral drugs are more powerful and patients taking injectable drugs report more side effects and adherence issues.
WHO will release new, more-specific recommendations for TB treatment later this year.
“Implementation of the new recommendations should happen quickly given landmark changes to the treatment of multidrug-resistant and rifampicin-resistant tuberculosis; nevertheless, it will be important to minimize disruptions to national health systems while ensuring that patient diagnosis and treatment continues to increase and improve,” the agency said.
The agency is launching a task force to help countries with a high burden of multidrug-resistant TB implement the new recommendations.
More articles on clinical leadership and infection control:
NIH conducts trial of live, weakened Zika vaccine in humans
Why the latest Ebola outbreak is worrying health officials
200 patients tested for hepatitis, HIV due to improperly sterilized surgical tools at Colorado health center
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
